{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:38Z","timestamp":1787037998394,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Funded by the China Healthcare Development Foundation"},{"name":"High-Quality Development Research Project on Hospital Pharmacy","award":["NIHAYS2410"],"award-info":[{"award-number":["NIHAYS2410"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04156-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:31:52Z","timestamp":1785555112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"6","key":"4156_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.hoc.2017.08.006","volume":"31","author":"H Rose-Inman","year":"2017","unstructured":"Rose-Inman H, Kuehl D (2017) Acute leukemia. Hematol Oncol Clin North Am 31(6):1011\u20131028","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"4156_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11912-020-01010-w","volume":"23","author":"TB Alexander","year":"2021","unstructured":"Alexander TB, Orgel E (2021) Mixed phenotype acute leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep 23(2):22","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4156_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A (2024) How i treat refractory and relapsed acute myeloid leukemia. Blood 143(1):11\u201320","journal-title":"Blood"},{"issue":"1","key":"4156_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2643-3230.BCD-24-0171","volume":"6","author":"H Goulart","year":"2025","unstructured":"Goulart H, Kantarjian H, Pemmaraju N et al (2025) Venetoclax-based combination regimens in acute myeloid leukemia. Blood Cancer Discov 6(1):23\u201337","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"4156_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A et al (2021) Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow\u2043up from a phase 1b study. Am J Hematol 96(2):208\u2013217","journal-title":"Am J Hematol"},{"issue":"15","key":"4156_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ et al (2019) Venetoclax combined with low\u2043dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase \u2160 b\/\u2161 study[J]. J Clin Oncol 37(15):1277\u20131284","journal-title":"J Clin Oncol"},{"issue":"24","key":"4156_CR7","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137\u20132145","journal-title":"Blood"},{"issue":"11","key":"4156_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem AH, Agarwal SK, Dunbar M et al (2016) Effect of low and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol 56(11):1355\u20131361","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4156_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","volume":"7","author":"TT Cheung","year":"2018","unstructured":"Cheung TT, Salem AH, Menon RM et al (2018) Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects. Clin Pharmacol Drug Dev 7(4):435\u2013440","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7571","key":"4156_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"1000 Genomes Project Consortium, Auton A, Brooks LD et al (2015) A global reference for human genetic variation. Nature 526(7571):68\u201374","journal-title":"Nature"},{"issue":"8","key":"4156_CR11","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s11095-022-03289-9","volume":"39","author":"J Dong","year":"2022","unstructured":"Dong J, Liu SB, Rasheduzzaman JM et al (2022) Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax. Pharm Res 39(8):1921\u20131933","journal-title":"Pharm Res"},{"issue":"1","key":"4156_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/jcph.2140","volume":"63","author":"D Mukherjee","year":"2023","unstructured":"Mukherjee D, Brackman DJ, Suleiman AA et al (2023) Impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics: a PBPK and population PK-informed analysis. J Clin Pharmacol 63(1):119\u2013125","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"4156_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","volume":"48","author":"MS Chiney","year":"2018","unstructured":"Chiney MS, Menon RM, Bueno OF et al (2018) Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica 48(9):904\u2013910","journal-title":"Xenobiotica"},{"issue":"8","key":"4156_CR14","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1007\/s12325-022-02170-w","volume":"39","author":"D Samineni","year":"2022","unstructured":"Samineni D, Gibiansky L, Wang B et al (2022) Pharmacokinetics and exposure-response analysis of venetoclax\u2009+\u2009obinutuzumab in chronic lymphocytic leukemia: phase 1b study and phase 3 CLL14 trial. Adv Ther 39(8):3635\u20133653","journal-title":"Adv Ther"},{"key":"4156_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1710282","volume":"16","author":"J Chen","year":"2026","unstructured":"Chen J, Yang X, Xie J et al (2026) Venetoclax concentration affects the incidence of haematological adverse events in patients with acute myeloid leukaemia. Front Pharmacol 16:1710282","journal-title":"Front Pharmacol"},{"issue":"2","key":"4156_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-024-04673-5","volume":"94","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Sato H, Miura M et al (2024) Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia. Cancer Chemother Pharmacol 94(2):285\u2013296","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"4156_CR17","first-page":"e2129","volume":"7","author":"S Rajme-L\u00f3pez","year":"2024","unstructured":"Rajme-L\u00f3pez S, Tello-Mercado AC, Ort\u00edz-Brizuela E et al (2024) Clinical and Microbiological Characteristics of Febrile Neutropenia During Induction Chemotherapy in Adults With Acute Leukemia[J]. Cancer Rep (Hoboken) 7(8):e2129","journal-title":"Cancer Rep (Hoboken)"},{"issue":"24","key":"4156_CR18","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1182\/bloodadvances.2024014291","volume":"8","author":"KV Pal","year":"2024","unstructured":"Pal KV, Othus M, Ali Z et al (2024) Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia. Blood Adv 8(24):6161\u20136170","journal-title":"Blood Adv"},{"issue":"4","key":"4156_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00277-023-05143-3","volume":"102","author":"K Matsuda","year":"2023","unstructured":"Matsuda K, Yoshida T, Sugimoto K (2023) High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia. Ann Hematol 102(4):971\u2013972","journal-title":"Ann Hematol"},{"issue":"8","key":"4156_CR20","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s00277-024-05676-1","volume":"103","author":"MF Kt","year":"2024","unstructured":"Kt MF, Semwal M, Yoosuf BT et al (2024) Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS. Ann Hematol 103(8):3179\u20133191","journal-title":"Ann Hematol"},{"issue":"25","key":"4156_CR21","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39(25):2768\u20132778","journal-title":"J Clin Oncol"},{"issue":"1","key":"4156_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41698-024-00740-5","volume":"8","author":"X Wen","year":"2024","unstructured":"Wen X, Lu Y, Li Y et al (2024) Remission rate, toxicity and pharmacokinetics of venetoclax-based induction regimens in untreated pediatric acute myeloid leukemia[J]. NPJ Precis Oncol 8(1):248","journal-title":"NPJ Precis Oncol"},{"issue":"8","key":"4156_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826\u2013833","journal-title":"J Clin Oncol"},{"issue":"12","key":"4156_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5738","volume":"37","author":"YL Yang","year":"2023","unstructured":"Yang YL, Qian ZY, Zhao Y et al (2023) LC-MS\/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid. Biomed Chromatogr 37(12):e5738","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"4156_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/pgs-2016-0179","volume":"18","author":"GX Hu","year":"2017","unstructured":"Hu GX, Dai DP, Wang H et al (2017) Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics 18(4):369\u2013379","journal-title":"Pharmacogenomics"},{"issue":"4","key":"4156_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/sj.clpt.6100046","volume":"81","author":"HJ Park","year":"2007","unstructured":"Park HJ, Shinn HK, Ryu SH et al (2007) Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 81(4):539\u2013546","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"4156_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J et al (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist 27(8):625\u2013636","journal-title":"Oncologist"},{"issue":"11","key":"4156_CR28","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1007\/s00277-024-05845-2","volume":"103","author":"M Hagihara","year":"2024","unstructured":"Hagihara M, Yasu T, Gando Y et al (2024) Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia. Ann Hematol 103(11):4497\u20134502","journal-title":"Ann Hematol"},{"issue":"3","key":"4156_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/10428194.2023.2290465","volume":"65","author":"L Wang","year":"2024","unstructured":"Wang L, Gao L, Liang Z et al (2024) Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study. Leuk Lymphoma 65(3):353\u2013362","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4156_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27051607","volume":"27","author":"X Yang","year":"2022","unstructured":"Yang X, Mei C, He X et al (2022) Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method. Molecules 27(5):1607","journal-title":"Molecules"},{"key":"4156_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.639854","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen M, Chen H et al (2021) Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation. Front Pharmacol 12:639854","journal-title":"Front Pharmacol"},{"key":"4156_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112090","volume":"133","author":"F Cheng","year":"2024","unstructured":"Cheng F, Cui Z, Li Q et al (2024) Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia. Int Immunopharmacol 133:112090","journal-title":"Int Immunopharmacol"},{"key":"4156_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y et al (2017) Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in human and characterization of its unusual metabolites. Drug Metab Dispos 45:294\u2013305","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"4156_CR34","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","volume":"99","author":"JE Meg\u00edas-Vericat","year":"2020","unstructured":"Meg\u00edas-Vericat JE, Solana-Altabella A, Ballesta-L\u00f3pez O et al (2020) Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol 99(9):1989\u20132007","journal-title":"Ann Hematol"},{"issue":"6","key":"4156_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41397-024-00359-6","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, Wan Q, Wan J et al (2024) Plasma concentrations of venetoclax and pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study. Pharmacogenomics J 24(6):37","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"4156_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J et al (2017) Management of venetoclax\u2043posaconazole interaction in acute myeloid leukemia patients:evaluation of dose adjustments. Clin Ther 39(2):359\u2013367","journal-title":"Clin Ther"},{"issue":"12","key":"4156_CR37","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N (2025) How I treat patients with AML using azacitidine and venetoclax. Blood 145(12):1237\u20131250","journal-title":"Blood"},{"issue":"3","key":"4156_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T et al (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol 102(3):541\u2013546","journal-title":"Ann Hematol"},{"key":"4156_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2026.108204","volume":"164","author":"A Ambinder","year":"2026","unstructured":"Ambinder A, Levis M, Wang X et al (2026) A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy. Leuk Res 164:108204","journal-title":"Leuk Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04156-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:29Z","timestamp":1787036129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04156-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04156-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8247030\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.22541\/au.175214523.36120860\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"224"}}